Showing 1951-1960 of 2150 results for "".
- Horus Pharma Launches Neovis Total Multi for Dry Eye in New Sizehttps://modernod.com/news/horus-pharma-launches-neovis-total-multi-for-dry-eye-in-new-size/2476843/Horus Pharma announced the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian, and Spanish markets. The product is prescribed as third-line therapy for the treatment of dry eyes with keratitis or dry keratoconjunctivitis, following unsuccessful treatment with low-viscosity
- Topcon Announces the Release of Harmony Into the EMEA Regionhttps://modernod.com/news/topcon-announces-the-release-of-harmony-into-the-emea-region/2476835/Topcon has announced the release and clearance of the Topcon Harmony, a class II medical diagnostic software, into the EMEA market. Topcon Harmony is a responsive browser-based software application for on-site or cloud-hosted environments that allows practitioners to connect all of their diagnost
- Now Optics Names Two Women to its Executive Leadership Teamhttps://modernod.com/news/now-optics-names-two-women-to-its-executive-leadership-team/2476834/Now Optics recently named two women to its leadership team. Former CVS Health’s Morgan Diaz joined Now Optics as senior vice president of operations and business development, and Lukana Justin previously from Office Depot Inc. is the new, senior vice president of marketing. They join Tara Pellegr
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- MIGS Devices Continue to Expand Use of Glaucoma Surgeryhttps://modernod.com/news/migs-devices-continue-to-expand-use-of-glaucoma-surgery/2476811/Minimally invasive glaucoma surgery (MIGS) stents account for nearly half of all glaucoma surgical device revenue in 2019, according to a Market Scope report. Market penetration of these stents over the past 5 years has been impressive, but the voluntary recall of the Alcon CyPass in 2018
- US Outlines Plans to Allow Importation of Certain Prescription Drugs From Canada, Other Countrieshttps://modernod.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/The US Department of Health and Human Services (HHS) on Wednesday outlined details of two potential pathways that will allow the importation of certain prescription medicines originally intended for foreign markets. The announcement comes the day after HHS Secretary Alex Azar confirmed that Presi
- Novartis, Mundipharma Ink Partnership to Enhance Access to Three Asian Countries to Established Medicine Brands for Glaucoma and External Eye Diseaseshttps://modernod.com/news/novartis-mundipharma-ink-partnership-to-enhance-access-to-three-asian-countries-to-established-medicine-brands-for-glaucoma-and-external-eye-diseases/2476771/Novartis and Mundipharma have signed a landmark agreement for the marketing, sales and distribution rights of Novartis medicines in the general ophthalmology disease area in Taiwan of Novartis. This includes medicines for glaucoma and external eye diseases. This f
- Medicel Launches First 2-in-1 Lens Injection Systemhttps://modernod.com/news/medicel-launches-first-2-in-1-lens-injection-system/2476740/Medicel says it has launched the world’s first 100% 2-in-1 lens injector, the Accuject Dual. The new injector enables surgeons to operate either in push or screw mode, allowing more control. Unlike competitor dual-mode injectors on the market that are 50% push and 50% screw, the Accuject
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Ophtec Partners With VSA in Argentina to Commercialize Ophtec’s Productshttps://modernod.com/news/ophtec-partners-with-vsa-in-argentina-to-commercialize-ophtecs-products/2476630/Ophtec BV announced that it has signed a partnership agreement with VSA to commercialize Ophtec’s products in the Argentinian marketplace. The Precizon IOL line as well as the Artisan and Artiflex line of iris fixated IOLs are some of the products that will be commercialized by VSA. “Ophte